<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322539</url>
  </required_header>
  <id_info>
    <org_study_id>2019-013-GLOB1</org_study_id>
    <nct_id>NCT04322539</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer</brief_title>
  <acronym>FRESCO-2</acronym>
  <official_title>A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical&#xD;
      trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC)&#xD;
      versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). 687&#xD;
      subjects will be randomized to one of the following treatment arms in a 2:1 ratio,&#xD;
      fruquintinib plus BSC or placebo plus BSC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical&#xD;
      trial to compare the efficacy and safety of fruquintinib in combination with BSC versus&#xD;
      placebo in combination with BSC in advanced colorectal cancer patients who have progressed&#xD;
      on, or were intolerant to, chemotherapy, biologics, and TAS-102 or regorafenib. Patients with&#xD;
      MSI-H/MMR deficient tumors must have also received an immune checkpoint inhibitor if approved&#xD;
      and available and if deemed appropriate. Subjects with BRAF-mutant tumors must have been&#xD;
      treated with a BRAF inhibitor if approved and available and if deemed appropriate.&#xD;
&#xD;
      Metastatic colorectal cancer cannot be cured by surgery. Therefore, treatment principals are&#xD;
      primarily aimed at controlling disease progression and prolonging survival. Standard first-&#xD;
      and second-line therapy includes cytotoxic drugs such as 5-fluorouracil, oxaliplatin, and&#xD;
      irinotecan; anti-VEGF therapy; and, if RAS wild type, anti-EGFR therapy. After the first two&#xD;
      lines of chemotherapy, standard third-line treatment is either TAS-102 or regorafenib. There&#xD;
      are currently no effective treatments for patients who have progressed on standard, approved&#xD;
      therapies, and treatment options include reuse of prior therapies, clinical trials or BSC.&#xD;
      Consequently, there is an unmet medical need for additional safe and effective treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>To evaluate the overall survival of fruquintinib plus BSC compared to placebo plus BSC in subjects with refractory mCRC.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">687</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Metastatic Colon Cancer</condition>
  <arm_group>
    <arm_group_label>fruquintinib plus best supportive care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, subjects will receive active study drug plus best supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo plus best supportive care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm, subjects will receive placebo plus best supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Oral VEGFR inhibitor</description>
    <arm_group_label>fruquintinib plus best supportive care</arm_group_label>
    <other_name>HMPL-013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>placebo plus best supportive care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Histologically and/or cytologically documented metastatic colorectal adenocarcinoma.&#xD;
             RAS, BRAF, and microsatellite instability microsatellite instability (MSI)/mismatch&#xD;
             repair (MMR) status for each patient must be documented, according to country level&#xD;
             guidelines;&#xD;
&#xD;
          -  Subjects must have progressed on or been intolerant to treatment with either&#xD;
             trifluridine/tipiracil (TAS-102) or regorafenib. Subjects are considered intolerant to&#xD;
             TAS-102 or regorafenib if they have received at least 1 dose of either agents and were&#xD;
             discontinued from therapy for reasons other than disease progression. Subjects who&#xD;
             have been treated with both TAS-102 and regorafenib are permitted. Subjects must also&#xD;
             have been previously treated with standard approved therapies: fluoropyrimidine-,&#xD;
             oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and,&#xD;
             if RAS wild-type, an anti-EGFR therapy;&#xD;
&#xD;
          -  Subjects with microsatellite-high (MSI-H) or mismatch repair deficient (dMMR) tumors&#xD;
             must have been treated with immune checkpoint inhibitors if approved and available in&#xD;
             the subject's country unless the patient is ineligible for treatment with a checkpoint&#xD;
             inhibitor;&#xD;
&#xD;
          -  Subjects who received oxaliplatin in the adjuvant setting and developed metastatic&#xD;
             disease during or within 6 months of completing adjuvant therapy are considered&#xD;
             eligible without receiving oxaliplatin in the metastatic setting. Subjects who&#xD;
             developed metastatic disease more than 6 months after completion of&#xD;
             oxaliplatin-containing adjuvant treatment must be treated with oxaliplatin-based&#xD;
             therapy in the metastatic setting to be eligible;&#xD;
&#xD;
          -  Body weight ≥40kg;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;&#xD;
&#xD;
          -  Have measurable disease according to RECIST Version 1.1, assessed locally. Tumors that&#xD;
             were treated with radiotherapy are not measurable per RECIST Version 1.1, unless there&#xD;
             has been documented progression of those lesions;&#xD;
&#xD;
          -  Expected survival &gt;12 weeks.&#xD;
&#xD;
          -  For female subjects of childbearing potential and male subjects with partners of&#xD;
             childbearing potential, agreement to use a highly effective form(s) of contraception,&#xD;
             that results in a low failure rate (&lt;1% per year) when used consistently and&#xD;
             correctly, starting during the screening period, continuing throughout the entire&#xD;
             study period, and for 90 days after taking the last dose of study drug. Such methods&#xD;
             include: oral hormonal contraception (combined estrogen/ progestogen, or&#xD;
             progestogen-only) associated with inhibition of ovulation, intrauterine device (IUD),&#xD;
             intrauterine hormone-releasing system (IUS), bilateral tubal ligation, vasectomized&#xD;
             partner, or true sexual abstinence in line with the preferred and usual lifestyle of&#xD;
             the subject. Highly effective contraception should always be combined with an&#xD;
             additional barrier method (eg, diaphragm, with spermicide). The same criteria are&#xD;
             applicable to male subjects involved in this clinical trial if they have a partner of&#xD;
             childbirth potential, and male subjects must always use a condom.&#xD;
&#xD;
          -  Subjects with BRAF-mutant tumors must have been treated with a BRAF inhibitor if&#xD;
             approved and available in the subject's home country unless the patient is ineligible&#xD;
             for treatment with a BRAF inhibitor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1.5×109/L, platelet count &lt;100×109/L, or hemoglobin&#xD;
             &lt;9.0 g/dL. Blood transfusion within 1 week prior to enrollment for the purpose of&#xD;
             increasing the likelihood of eligibility is not allowed;&#xD;
&#xD;
          -  Serum total bilirubin &gt;1.5 × the upper limit of normal (ULN). Patients with Gilbert&#xD;
             syndrome, bilirubin &lt;2 X ULN, and normal AST/ALT are eligible;&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5 × ULN in&#xD;
             patients without hepatic metastases; ALT or AST &gt;5 × ULN in patients with hepatic&#xD;
             metastases;&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 × ULN or creatinine clearance &lt;60 mL/min. Creatinine clearance&#xD;
             can either be measured in a 24-hour urine collection or estimated by the&#xD;
             Cockroft-Gault equation.&#xD;
&#xD;
          -  Urine dipstick protein ≥2+ or 24-hour urine protein ≥1.0 g/24-h. Subjects with greater&#xD;
             than 2+ proteinuria by dipstick must undergo a 24-hour urine collection to assess&#xD;
             urine protein level;&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as: systolic blood pressure ≥140 mm Hg and/or&#xD;
             diastolic blood pressure ≥90 mm Hg despite optimal medical management;&#xD;
&#xD;
          -  International Normalized Ratio (INR) &gt;1.5 x ULN or activated partial thromboplastin&#xD;
             time (aPTT) &gt;1.5 × ULN, unless the patient is currently receiving or intended to&#xD;
             receive anticoagulants for prophylactic purposes;&#xD;
&#xD;
          -  History of, or active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage&#xD;
             of an unresected gastrointestinal tumor, history of perforation or fistulas; or any&#xD;
             other condition that could, in the investigator's judgment, result in gastrointestinal&#xD;
             hemorrhage or perforation; within the 6 months prior to screening;&#xD;
&#xD;
          -  History or presence of hemorrhage from any other site (eg, hemoptysis or hematemesis)&#xD;
             within 2 months prior to screening;&#xD;
&#xD;
          -  History of a thromboembolic event, including deep vein thrombosis (DVT), pulmonary&#xD;
             embolism (PE), or arterial embolism within 6 months prior to screening.&#xD;
&#xD;
          -  Stroke and/or transient ischemic attack within 12 months prior to screening;&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, including but not limited to acute&#xD;
             myocardial infarction or coronary artery bypass surgery within 6 months prior to&#xD;
             enrollment, severe or unstable angina pectoris, New York Heart Association Class&#xD;
             III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left&#xD;
             ventricular ejection fraction (LVEF) &lt;50% by echocardiogram;&#xD;
&#xD;
          -  Mean corrected QT interval using the Fridericia method (QTcF) &gt;480 msec or any factors&#xD;
             that increase the risk of QTc prolongation or risk of arrhythmic events such as&#xD;
             hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or&#xD;
             unexplained sudden death under 40 years of age in a first-degree relative.&#xD;
&#xD;
          -  Concomitant medications with a known risk of causing QT prolongation and/or Torsades&#xD;
             de Pointes.&#xD;
&#xD;
          -  Systemic anti-neoplastic therapies (except for those described in Exclusion 18) or any&#xD;
             investigational therapy within 4 weeks prior to the first dose of study drug,&#xD;
             including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy and&#xD;
             immunotherapy;&#xD;
&#xD;
          -  Systemic small molecule targeted therapies (eg, tyrosine kinase inhibitors) within 5&#xD;
             half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;&#xD;
&#xD;
          -  Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the&#xD;
             initiation of study drug;&#xD;
&#xD;
          -  Brachytherapy (i.e., implantation of radioactive seeds) within 60 days prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Use of strong inducers or inhibitors of CYP3A4 within 2 weeks (or 5 half-lives,&#xD;
             whichever is longer) before the first dose of study drug;&#xD;
&#xD;
          -  Surgery or invasive procedure (i.e., a procedure that includes a biopsy; central&#xD;
             venous catheter placement is allowed) within 60 days prior to the first dose of study&#xD;
             drug or unhealed surgical incision;&#xD;
&#xD;
          -  Any unresolved toxicities from a previous antitumor treatment greater than CTCAE v5.0&#xD;
             Grade 1 (except for alopecia or neurotoxicity grade≤2);&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  Known history of active viral hepatitis. For patients with evidence of chronic&#xD;
             hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on&#xD;
             suppressive therapy, if indicated. Patients with HCV infection who are currently on&#xD;
             treatment are eligible if they have an undetectable HCV viral load.&#xD;
&#xD;
          -  Clinically uncontrolled active infection requiring IV antibiotics;&#xD;
&#xD;
          -  Tumor invasion of a large vascular structure, eg, pulmonary artery, superior or&#xD;
             inferior vena cava;&#xD;
&#xD;
          -  Women who are pregnant or lactating;&#xD;
&#xD;
          -  Brain metastases and/or spinal cord compression untreated with surgery and/or&#xD;
             radiotherapy, and without clinical imaging evidence of stable disease for 14 days or&#xD;
             longer; patients requiring steroids within 4 weeks prior to start of study treatment&#xD;
             are excluded;&#xD;
&#xD;
          -  Other malignancy, except for non-melanoma skin cancer, in situ cervical ca or bladder&#xD;
             ca (Tis and T1) that have been adequately treated during the 5 years prior to&#xD;
             screening;&#xD;
&#xD;
          -  Inability to take medication orally, dysphagia or an active gastric ulcer resulting&#xD;
             from previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or&#xD;
             any other condition that investigators believe may affect absorption of the&#xD;
             investigational product;&#xD;
&#xD;
          -  Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory&#xD;
             result, or any other condition (e.g., current alcohol or drug abuse) that&#xD;
             investigators suspect may prohibit use of the investigational product, affect&#xD;
             interpretation of study results, or put the patient at undue risk of harm based on the&#xD;
             investigator's assessment;&#xD;
&#xD;
          -  Known hypersensitivity to fruquintinib (or placebo) or any of its inactive ingredients&#xD;
             including the azo dyes Tartrazine - FD&amp;C Yellow 5 and Sunset yellow FCF - FD&amp;C Yellow&#xD;
             6;&#xD;
&#xD;
          -  Subjects who have received prior fruquintinib;&#xD;
&#xD;
          -  Live vaccine &lt;28days before the first dose of study drug(s). Seasonal vaccines for&#xD;
             influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are&#xD;
             live vaccines and are not allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Schelman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison MediPharma International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Fernandez</last_name>
    <phone>+1-973-567-3891</phone>
    <email>albertof@hutch-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keneikia Morgan</last_name>
    <email>keneikiam@hutch-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Brooks, MD</last_name>
    </contact>
    <investigator>
      <last_name>Donald Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Research Institute (CRI)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghassan Al-Jazayrly</last_name>
    </contact>
    <investigator>
      <last_name>Ghassan Al-Jazayrly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwan Fakih, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marwan Fakih, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujatha Nallapareddy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sujatha Nallapareddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjan Patel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anjan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute-S-Ft. Myers (FCS South)</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjan Patel</last_name>
    </contact>
    <investigator>
      <last_name>Anjan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Jeremy Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Cusnir, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mike Cusnir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of Brevard, Inc.</name>
      <address>
        <city>Palm Bay</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venkat Kancharla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Venkat Kancharla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Patel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute-N-St Pete (FCS North)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Patel</last_name>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Tallahassee East</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viralkumar Bhanderi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Viralkumar Bhanderi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute-Pan-Tallahassee (FCS Panhandle)</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viralkumar Bhanderi</last_name>
    </contact>
    <investigator>
      <last_name>Viralkumar Bhanderi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists WPB</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Gersten, MD</last_name>
    </contact>
    <investigator>
      <last_name>Todd Gersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research-E-WPB (Florida Cancer Specialists-FCS East)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine McQuade, MD</last_name>
    </contact>
    <investigator>
      <last_name>Todd Gersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Wu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christina Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Siegel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Oncologists</name>
      <address>
        <city>Chicago Ridge</city>
        <state>Illinois</state>
        <zip>60415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rami Haddad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rami Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ardaman Shergill, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ardaman Shergill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XCancer / Central Care Cancer Center</name>
      <address>
        <city>Garden City</city>
        <state>Kansas</state>
        <zip>67846</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Velasco</last_name>
    </contact>
    <investigator>
      <last_name>Jose Velasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville - James Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Sharma, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vivek Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Audubon</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Driscoll, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Driscoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Castine</last_name>
    </contact>
    <investigator>
      <last_name>Michael Castine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XCancer / Pontchartrain Cancer Center</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Oubre</last_name>
    </contact>
    <investigator>
      <last_name>David Oubre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousuf Gaffar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yousuf Gaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Krauss, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Krauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Shields, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Shields, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Larson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Timothy Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Joleen Hubbard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaswinder Singh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jaswinder Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadi Braiteh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Hochster, MD</last_name>
    </contact>
    <investigator>
      <last_name>Howard Hochster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XCancer / New Mexico Oncology &amp; Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amyn Aldina</last_name>
    </contact>
    <investigator>
      <last_name>Amyn Aldina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charleston Oncology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Lingerfelt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brian Lingerfelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Bendell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Eng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cathy Eng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Cline, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vivian Cline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Paulson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Scott Paulson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Baylor Sammons</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Paulson</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Paulson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology El Paso - Grandview</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Sanchez-Rivera, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ines Sanchez-Rivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inez Sanchez-Riviera</last_name>
    </contact>
    <investigator>
      <last_name>Inez Sanchez-Riviera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Dasari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arvind Dasari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Ratnam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Suresh Ratnam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Ratnam</last_name>
    </contact>
    <investigator>
      <last_name>Suresh Ratnam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nathan Shumway</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Shumway, DO</last_name>
    </contact>
    <investigator>
      <last_name>Nathan Shumway, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Shumway</last_name>
    </contact>
    <investigator>
      <last_name>Nathan Shumway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Richards, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Balderas</last_name>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>David Chang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer Partnership</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Kundra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ajay Kundra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cosgrove, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Cosgrove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin/ Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Zindars</last_name>
      <phone>414-805-8913</phone>
      <email>szindars@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Ben George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Clinical Oncology Network Pty Ltd (Icon)</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4001</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Coward, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jim Coward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Price, MD</last_name>
    </contact>
    <investigator>
      <last_name>Timothy Price, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Karapetis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christos Karapetis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Gibbs, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Gibbs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hopistal Medical Oncology Unit</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Chong, MD</last_name>
    </contact>
    <investigator>
      <last_name>Geoffrey Chong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Segelov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eva Segelov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical Research Services</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Khattak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adnan Khattak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <state>AUT</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Rumpold, MD</last_name>
    </contact>
    <investigator>
      <last_name>Holger Rumpold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schwerpunktkrankenhaus Feldkirch</name>
      <address>
        <city>Rankweil</city>
        <state>AUT</state>
        <zip>6830</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Winder, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Winder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Steyr</name>
      <address>
        <city>Steyr</city>
        <state>AUT</state>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Schreil, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Schreil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <state>AUT</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Piringer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gudrun Piringer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>AUT</state>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigit Gruenberger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brigit Gruenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wiener Gesundheitsverbund - Klinik Ottakring</name>
      <address>
        <city>Wien</city>
        <state>AUT</state>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Niedersuess-Beke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dora Niedersuess-Beke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis OLV - Campus Aalst</name>
      <address>
        <city>Aalst</city>
        <state>BEL</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabrina Bas, MD</last_name>
      <phone>+32 (0)53 72.45.02</phone>
      <email>sofie.tombeur@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Koen Hendrickx, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL St-Luc</name>
      <address>
        <city>Brussels</city>
        <state>BEL</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Van Den Eynde, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Van Den Eynde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>BEL</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Sinapi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Sinapi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>BEL</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy De Clercq</last_name>
      <phone>+ 32 3 821 53 07</phone>
      <email>peggy.de.clercq@uza.be</email>
    </contact>
    <investigator>
      <last_name>Marc Peeters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centres Hospitaliers Jolimont</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <state>BEL</state>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Delaunoit, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Delaunoit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>BEL</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Van Cutsem, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Van Cutsem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta Roeselare</name>
      <address>
        <city>Roeselare</city>
        <state>BEL</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Decaestecker, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jochen Decaestecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <state>BEL</state>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jos Janssens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jos Janssens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>BEL</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Faugeras, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence Faugeras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique CHC MontLegia</name>
      <address>
        <city>Liège</city>
        <state>Wallonia</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gauthier Demolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lige - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liège</city>
        <state>Wallonia</state>
        <zip>4001</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joelle Collignong, M</last_name>
      <email>joelle.collignon@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Marchal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital Centre of Oncology</name>
      <address>
        <city>Tallinn</city>
        <state>Harju</state>
        <zip>11312</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksei Daljajev</last_name>
      <email>aleksei.daljajev@itk.ee</email>
    </contact>
    <investigator>
      <last_name>Gerli Kuusk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sihtasutus Pohja-Eesti Regionaalhaigla (PERH) (North Estonia Medical Centre)</name>
      <address>
        <city>Tallinn</city>
        <state>Harju</state>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maret Altmae</last_name>
      <email>maret.altmae@regionaalhaigla.ee</email>
    </contact>
    <investigator>
      <last_name>Anneli Elme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital Clinic of Haematology and Oncology</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Saar, MD</last_name>
      <email>kristi.saar@kliinikum.ee</email>
    </contact>
    <investigator>
      <last_name>Andrus Magi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besancon</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Comte</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Berthod</last_name>
      <email>dberthod@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <state>FRA</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Pernot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Simon Pernot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unicancer</name>
      <address>
        <city>Caen</city>
        <state>FRA</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie Parzy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurelie Parzy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <state>FRA</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Ghiringhelli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francois Ghiringhelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM-Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <state>FRA</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibault Mazard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thibault Mazard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <state>FRA</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Aparicio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Aparicio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital St Antoine</name>
      <address>
        <city>Paris</city>
        <state>FRA</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Trouilloud, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Trouilloud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salptriere</name>
      <address>
        <city>Paris</city>
        <state>FRA</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Bachet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Baptiste Bachet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <state>FRA</state>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violaine Randrian, MD</last_name>
    </contact>
    <investigator>
      <last_name>Violaine Randrian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <state>FRA</state>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Baconnier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu Baconnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire CHU de Rennes - Hopital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>FRA</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Lievre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Astrid Lievre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie Strasbourg-Europe</name>
      <address>
        <city>Strasbourg</city>
        <state>FRA</state>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meher Ben Abdelghani, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meher Ben Abdelghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Paris</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Ducreux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch Saarow</name>
      <address>
        <city>Berlin</city>
        <state>DEU</state>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Reichardt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Reichardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <state>DEU</state>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominik Modest, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominik Modest, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <state>DEU</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gunnar Folprecht, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gunnar Folprecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>DEU</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juergen Siebler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juergen Siebler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <state>DEU</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kasper-Virchow, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Kasper-Virchow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut fr Klinisch Onkologische ForschungKrankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt Am Main</city>
        <state>DEU</state>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salah-Eddin Al-Batran, MD</last_name>
    </contact>
    <investigator>
      <last_name>Salah-Eddin Al-Batran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haematologisch-Onkologische Praxis Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>DEU</state>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eray Goekkurt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eray Goekkurt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Tumorzentrum Hamburg AK Altona</name>
      <address>
        <city>Hamburg</city>
        <state>DEU</state>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Arnold, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dirk Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaet zu Koeln - Uniklinik Koeln</name>
      <address>
        <city>Koeln</city>
        <state>DEU</state>
        <zip>D-50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armin Tuchscherer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Armin Tuchscherer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaeres Krebszentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>DEU</state>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Hacker, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ulrich Hacker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RKH Kliniken</name>
      <address>
        <city>Ludwigsburg</city>
        <state>DEU</state>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Angermeier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Angermeier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Haematologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <state>DEU</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hendrik Kroening, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hendrik Kroening, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Mannheim- III. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <state>DEU</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf-Dieter Hofheinz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ralf-Dieter Hofheinz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Neuperlach</name>
      <address>
        <city>Muenchen</city>
        <state>DEU</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meinolf Karthaus, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meinolf Karthaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum fÃ¼r HÃ¤matologie und Onkologie MVZ GmbH</name>
      <address>
        <city>Porta Westfalica</city>
        <state>DEU</state>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enno Moorahend, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eno Moorahend, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Del-Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet, Szent Laszlo Korhaz</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyorgy Bodoky, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gyorgy Bodoky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hitre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Erika Hitre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>H-1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Papai, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zsuzsanna Papai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <state>HUN</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Arkosy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Arkosy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bacs- Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <state>HUN</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judit Kocsis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Judit Kocsis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg megyei Korhazak es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>HUN</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozsef Erfan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jozsef Erfan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hetenyi G Korhaz, Onkologiai Kozpont</name>
      <address>
        <city>Szolnok</city>
        <state>HUN</state>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Csoszi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tibor Csoszi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szent Borbala Korhaz</name>
      <address>
        <city>Tatabanya</city>
        <state>HUN</state>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Uhlyarik, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Uhlyarik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologiai Osztaly</name>
      <address>
        <city>Kaposvár</city>
        <state>Somogy</state>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisztina Decsi</last_name>
      <phone>+36 30 670 4228</phone>
      <email>decsi.krisztina@kmmk.hu</email>
    </contact>
    <investigator>
      <last_name>Eva Ezer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Korhaz, Onkologiai Osztaly, F epulet 3. em.</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Pogacsas</last_name>
      <email>onkologia.zeg@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Karoly Mahr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Kozpont</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolett Kurucz-Asztalos</last_name>
      <phone>+36208289475</phone>
      <email>asztalos.nikolett9@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bassam Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Oncologica, Ospedali Riuniti Umberto 1</name>
      <address>
        <city>Ancona</city>
        <state>ITA</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rossana Berardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rossana Berardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza Hospital</name>
      <address>
        <city>Brescia</city>
        <state>ITA</state>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Zaniboni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Zaniboni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico San Martino di Genova</name>
      <address>
        <city>Genova</city>
        <state>ITA</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Sobrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Sobrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>ITA</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Di Bartolomeo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Di Bartolomeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>ITA</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Zampino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Zampino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <state>ITA</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bianchi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Bianchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione G. Pascale</name>
      <address>
        <city>Naples</city>
        <state>ITA</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Avallone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Avallone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto Irccs</name>
      <address>
        <city>Padova</city>
        <state>ITA</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Lonardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sara Lonardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>ITA</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Cremolini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chiara Cremolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda USL-IRCCS di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>ITA</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria C Banzi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria C Banzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Card G Panico</name>
      <address>
        <city>Tricase</city>
        <state>ITA</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Tamburini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emiliano Tamburini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est</name>
      <address>
        <city>Vicenza</city>
        <state>ITA</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Cappetta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Cappetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano MI</city>
        <state>Lombardy</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Sala</last_name>
      <email>simona.sala@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiki Masuishi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Toshiki Masuishi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisuke Kotani, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daisuke Kotani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama City</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomohiro Nishina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tomohiro Nishina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taito Esaki, MD</last_name>
    </contact>
    <investigator>
      <last_name>Taito Esaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshito Komatsu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yoshito Komatsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Sunakawa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yu Sunakawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama-shi</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisato Kawakami, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hisato Kawakami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taroh Satoh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Taroh Satoh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <state>Sunto-gun</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kentaro Yamazaki, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kentaro Yamazaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsuo Takashima, MD</last_name>
    </contact>
    <investigator>
      <last_name>Atsuo Takashima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall dHebron</name>
      <address>
        <city>Barcelona</city>
        <state>ESP</state>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Elez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Elez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofa</name>
      <address>
        <city>Córdoba</city>
        <state>ESP</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Ortiz Morales, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Jose Ortiz Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>ESP</state>
        <zip>3203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Gallego Plazas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Gallego Plazas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon HGUGM</name>
      <address>
        <city>Madrid</city>
        <state>ESP</state>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Garcia Alfonso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pilar Garcia Alfonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <state>ESP</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Ferreiro Monteagudo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Reyes Ferreiro Monteagudo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <state>ESP</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Suarez Lara</last_name>
      <phone>91 330 30 00</phone>
      <email>lydia.hcsc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier Sastre Valera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <state>ESP</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Garcia Carbonero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rocio Garcia Carbonero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <state>ESP</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Rodriguez Salas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nuria Rodriguez Salas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <state>ESP</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cubillo Gracian, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Cubillo Gracian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>ESP</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Sanchez Ruiz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Sanchez Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <state>ESP</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Alcaide Garcia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julia Alcaide Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>ESP</state>
        <zip>33013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Jimenez Fonseca, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paula Jimenez Fonseca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>ESP</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Rivera Herrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fernando Rivera Herrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ-nico Universitario de Santiago-CHUS</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>ESP</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Lopez Lopez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Lopez Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon HGUGM</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inez Perez</last_name>
      <phone>+34 91 426 96 29</phone>
      <email>i.pzfuente@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Garcia Alfonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Immaculada Robles</last_name>
      <phone>34955013068</phone>
      <email>i.robles.huvr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Luisa Limon Miron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luna Porta</last_name>
      <phone>34961 973 527</phone>
      <email>lporta@incliva.es</email>
    </contact>
    <investigator>
      <last_name>Susana Rosello Keranen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>GBR</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Macqullivray Samuel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leslie Macqullivray Samuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <state>GBR</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian T Chau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ian T Chau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>Middlesex</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Walaa</last_name>
      <email>Walaa.Hassan@hcahealthcare.co.uk</email>
    </contact>
    <investigator>
      <last_name>Hendrik-Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon</keyword>
  <keyword>colorectal</keyword>
  <keyword>mcrc</keyword>
  <keyword>crc</keyword>
  <keyword>metastatic colon</keyword>
  <keyword>metastatic colorectal</keyword>
  <keyword>VEGF</keyword>
  <keyword>VEGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

